AstraZeneca's Baxfendy wins EU panel backing for hypertension treatment
AZN•Baxfendy received a positive EU regulatory recommendation for adults whose hypertension is not sufficiently controlled by at least two medications. If approved, it would be the EU’s first aldosterone synthase inhibitor.
1. EU recommendation
AstraZeneca’s Baxfendy (baxdrostat) received a positive EU regulatory recommendation for adults with hypertension insufficiently controlled by at least two medications. If approved, Baxfendy would become the EU’s first aldosterone synthase inhibitor.
